VENUS: Ustekinumab Appears Superior to Vedolizumab for Crohn ' s VENUS: Ustekinumab Appears Superior to Vedolizumab for Crohn ' s

A retrospective analysis compares two biologic agents among patients with Crohn ' s disease who failed previous anti-TNF therapy.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news